KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Share-based Compensation for 4 consecutive years, with $42.8 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Share-based Compensation fell 60.4% year-over-year to $42.8 million, compared with a TTM value of $229.9 million through Dec 2023, down 88.09%, and an annual FY2025 reading of $81.5 million, down 27.41% over the prior year.
  • Share-based Compensation was $42.8 million for Q4 2023 at Ginkgo Bioworks Holdings, down from $52.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.6 billion in Q4 2021 and bottomed at $118000.0 in Q3 2020.
  • Average Share-based Compensation over 4 years is $289.7 million, with a median of $61.5 million recorded in 2023.
  • Peak annual rise in Share-based Compensation hit 553138.14% in 2022, while the deepest fall reached 93.2% in 2022.
  • Year by year, Share-based Compensation stood at $118000.0 in 2020, then surged by 1348422.03% to $1.6 billion in 2021, then crashed by 93.2% to $108.2 million in 2022, then crashed by 60.4% to $42.8 million in 2023.
  • Business Quant data shows Share-based Compensation for DNA at $42.8 million in Q4 2023, $52.6 million in Q3 2023, and $61.5 million in Q2 2023.